Looking at the universe of stocks we cover at Dividend Channel, on 9/29/17, RELM Wireless Corp. (RWC) will trade ex-dividend, for its quarterly dividend of $0.02, payable on 10/16/17. As a percentage of RWC's recent stock price of $3.75, this dividend works out to approximately 0.53%, so look for shares of RELM Wireless Corp. to trade 0.53% lower — all else being equal — when RWC shares open for trading on 9/29/17.Below is a dividend history chart for RWC, showing historical dividends prior to the most recent $0.02 declared by RELM Wireless Corp.: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from RWC is likely to continue, and whether the current estimated yield of 2.13% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of RWC shares, versus its 200 day moving average: Looking at the chart above, RWC's low point in its 52 week range is $3.40 per share, with $5.55 as the 52 week high point — that compares with a last trade of $3.80. In Wednesday trading, RELM Wireless Corp. shares are currently up about 1.4% on the day.
More from Stocks
Stocks Higher as Investors Look to Jerome Powell for Hints on Fed Policy
Stocks are rising Thursday with investors looking to guidance from Fed Chairman Jerome Powell, who is scheduled to speak Friday.
Nordstrom's Mixed Earnings -- What Wall Street Is Saying
Nordstrom's discounting is concerning some analysts, while others question how long the retailer can cut costs.
Toro's Stock Jumps as Lawnmower Maker Beats Earnings Estimates
The CEO attributes a big jump in quarterly sales to the company's acquisition of Charles Machine Works, a maker of underground construction equipment.
Going Shopping? Jim Cramer Breaks Down Nordstrom's Quarter, Oil and Markets
Jim Cramer weighs in on Nordstrom's quarter, his latest thoughts on oil and the markets.
Retrophin Tanks After Neurological Treatment Fails Late-Stage Study
The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.